secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001447028-24-000006
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO Collier retires, gets $207K bonus; interim CEO McElhaugh gets $515K salary + $127.5K stipend
--------------------------------------------------------------------------------

- William Collier retired as CEO effective Dec 31, 2023; receives prorated 50% target bonus of $207,058.
- Collier enters consulting agreement for 3 months at $400/hour; RSUs and stock options continue to vest during term.
- Michael McElhaugh appointed Interim President & CEO; base salary increased to $515,000, target bonus 45%, additional yearly stipend of $127,500.
- McElhaugh will be nominated for election to the Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000144702824000006/0001447028-24-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000144702824000006/abus-20231231.htm
  HTML page:      https://secwatch.observer/filing/0001447028-24-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer